Bone Graft Manufacturer Advances Randomized Trials in Spinal and Ankle Fusion .

Clinical evidence generation for synthetic bone graft substitutes continues to expand. Kuros Biosciences reported progress across 3 prospective trials evaluating its MagnetOs bone graft technology, with enrollment reaching 97% in PROOF, 55% in PRECISE and 18% in ASTRA. The studies investigate fusion applications in the spine and hindfoot or ankle. The company also reported 40% year-over-year medical device sales growth and expanded US manufacturing. These developments indicate growing clinical and commercial activity, although definitive comparative trial results are still pending.